Background: Numerous studies suggest that non-steroidal anti-inflammatory drugs reduce cancer
cell proliferation, progression, angiogenesis, apoptosis, and invasiveness.
Objective: The current study focuses on the evaluation of novel mefenamic acid derivatives for the treatment of
Methods: Derivatives were subjected to molecular modeling for prediction of pharmacological activity using
software, followed by synthesis and in vitro assay. In in vivo study, disease was induced with N-Nitrosodiethylamine
followed by 2-acetylaminofluorene orally for 2 weeks. After 12 weeks of induction, treatment was given for a
period of one week. At the end of the treatment, determination of liver weight, a number of nodules, biochemical
parameters, immunohistochemistry, histopathology, and gene expression studies, were carried out.
Results: Based on molecular docking score for PDGF-α (Platelet-Derived Growth Factor) and IC50 values in
HepG2 cell line study, JS-PFA was selected for the in vivo study where JS-PFA showed a statistically significant
reduction in a number of nodules and liver weight. Protective role of JS-PFA has been observed in tumorspecific
markers like α-fetoprotein, carcinoembryonic antigen, and lactate dehydrogenase levels. The JS-PFA
has shown a significant reduction in PDGF-α levels as well as liver markers and total bilirubin levels. Histopathological
analysis also showed a protective effect. The results of immunohistochemical analysis of P53 and
down-regulation of vascular endothelial growth factor and matrix metalloproteinases-9 genes suggest that derivative
inhibits PDGF mediated tumor growth and leads to apoptosis, inhibition of angiogenesis, and metastasis.
Conclusion: The effectiveness of JS-PFA in our studies suggests targeting PDGF by COX 2 inhibitor can serve
as a novel treatment strategy for the treatment of HCC.